AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase Ib study to evaluate the safety, tolerability, and
preliminary efficacy of AN0025 in combination with chemoradiotherapy (CRT) in patients with
locally advanced/locally recurrent esophageal cancer. This study will enroll different
cohorts of patients based on the assessment of original lesions, including patients that can
be surgically resected with potential (but primary resection without CRT is unlikely to
achieve clear margins as defined by MRI), patients with unresectable locally advanced
esophageal cancer or esophagogastric junction cancer, and patients with unresectable locally
recurrent esophageal cancer or esophagogastric junction cancer where the recurrent region has
not received radiotherapy. Histologic classification can be squamous cell carcinoma or
adenocarcinoma.